Skip to content
Search

Latest Stories

Meghan Markle opens up about 'scary' battle with rare post-partum condition

"It's so rare. And it's so scary," Meghan said during the recording

Meghan Markle Speaks Out on 'Scary' Journey With Rare Postpartum Illness

Meghan also discussed the challenge of balancing motherhood with professional commitments

Getty

The Duchess of Sussex has spoken publicly about a serious health scare she experienced after giving birth, revealing she suffered from post-partum pre-eclampsia.

Speaking on the first episode of her new podcast, Confessions of a Female Founder, Meghan described the condition as both "rare" and "scary", admitting she managed the situation privately without the public being aware. She did not specify whether the diagnosis came after the birth of her son Archie, now five, or her daughter Lilibet, aged three.


According to NHS guidelines, pre-eclampsia can affect women during pregnancy or shortly after delivery. Early symptoms typically include high blood pressure and can lead to severe complications if untreated.

"It's so rare. And it's so scary," Meghan said during the recording. "You're still trying to juggle everything, and the world doesn't know what's happening. Quietly, you're still trying to show up for people. Mostly, you're trying to show up for your children."

She described the experience as a "huge medical scare", underlining the emotional and physical demands she faced in silence.

Meghan’s guest on the podcast, Whitney Wolfe Herd — founder of the dating platform Bumble — also shared her experience with the condition. Herd said it was "life or death, truly" and recalled the intense media attention Meghan faced following the birth of Archie. "I'll never forget the image of you after having Archie, with the whole world waiting for his debut," she told Meghan.

During the episode, Meghan also discussed the challenge of balancing motherhood with professional commitments. She explained that much of her work is conducted from home, allowing her to be present for her children's daily routines.

"I don't leave the house to go to an office; my office is here," Meghan said. She added that her daughter Lilibet, who attends preschool for half days, often joins her in meetings when she wakes from her naps.

"If she wakes up and wants to find me, she knows where I am — even if my office door is closed. She'll sit on my lap during meetings, right there with a grid of executives on the screen," Meghan shared.

Despite the challenges, Meghan insisted she embraces the juggle between work and motherhood. "I wouldn't have it any other way. I don't want to miss pick-up if I don't have to. I don't want to miss drop-off."

The launch of Confessions of a Female Founder marks Meghan's return to podcasting after her previous series, Archetypes, which was released through Spotify but received mixed reviews. Her latest project is produced in collaboration with Lemonada Media and focuses on candid conversations with women about entrepreneurship, motherhood, and leadership.

Meghan is also juggling several other ventures, including a new Netflix lifestyle series, With Love, Meghan, and the launch of her lifestyle brand American Riviera Orchard.

In the podcast, she reflected on how parenting and building a business often mirror each other, requiring patience and perspective. "You're building something while your child is going through potty training," she joked. "Both are equally important. In my world, it's high value. In Lilibet's world, it’s high value too."

More For You

Mounjaro price rise

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro

iStock

Mounjaro’s highest dose to rise from £122 to £247.50, not £330

Highlights:

  • Eli Lilly had announced a steep price rise of up to 170% for Mounjaro.
  • A new discount deal with UK suppliers will limit the increase for patients.
  • Pharmacies will still apply a mark-up, but consumer costs are expected to rise less than initially feared.
  • NHS pricing remains unaffected due to separate arrangements.

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro, easing fears of a sharp rise in costs for UK patients. The new arrangement means that, from September, pharmacies and private services will face smaller wholesale increases than first expected, limiting the impact on consumers.

Why the price rise was announced

Earlier this month, Eli Lilly said it would raise Mounjaro’s list price by as much as 170%, which could have pushed the highest monthly dose from £122 to £330. The company argued that UK pricing needed to align more closely with higher costs in Europe and the United States.

Keep ReadingShow less
chicken-pox-istock

The Department of Health said the rollout would reduce missed days at nursery and school, cut time parents take off work, and save the NHS about £15 million a year. (Representational image: iStock)

iStock

England to introduce free chickenpox vaccine for children from 2026

CHILDREN in England will be offered a free chickenpox vaccine for the first time from January 2026, the government has announced.

GP practices will give eligible children a combined vaccine for measles, mumps, rubella and varicella (MMRV) as part of the routine childhood vaccination schedule. Around half a million children each year are expected to be protected.

Keep ReadingShow less
Serena Williams

Williams explained that her weight challenges began after the birth of her first daughter

Getty Images

Serena Williams says GLP-1 made her feel light physically and mentally after 31lb loss

Highlights:

  • Serena Williams reveals she has lost more than 31lbs using a GLP-1 medication
  • The tennis legend says the treatment enhanced her existing healthy lifestyle
  • She stresses that weight loss should not change self-image or self-confidence

Serena Williams has revealed she has lost more than 31lbs after turning to a weight-loss medication, saying the treatment has transformed both her body and her mindset.

The 23-time Grand Slam champion, 43, told PEOPLE that using a GLP-1 medication — a type of injection that works by regulating appetite — has helped enhance the healthy lifestyle she already maintained through diet and exercise.

Keep ReadingShow less
Monica Seles

Seles first began noticing symptoms around five years ago

Getty Images

Tennis champion Monica Seles reveals living with myasthenia gravis

Highlights:

  • Nine-time Grand Slam winner Monica Seles diagnosed with myasthenia gravis three years ago
  • The 51-year-old revealed her condition ahead of this month’s US Open to raise awareness
  • Disease causes muscle weakness and has no known cure

Former world number one Monica Seles has revealed she was diagnosed with myasthenia gravis, a rare neuromuscular autoimmune disease, three years ago. The 51-year-old, who won nine Grand Slam singles titles, went public ahead of the US Open to raise awareness of the condition, which causes muscle weakness and can affect multiple parts of the body.

Symptoms and diagnosis

Seles first began noticing symptoms around five years ago when she experienced double vision and struggled with coordination. “I would be playing [tennis] with some kids or family members, and I would miss a ball. I was like, ‘Yeah, I see two balls,’” she told the Associated Press. These symptoms eventually led to her diagnosis, which took time for her to come to terms with.

Keep ReadingShow less
faulty knee implant NHS recall

Hundreds of patients required corrective surgery

iStock

Faulty knee implant recalled after being used in over 10,000 NHS surgeries

Highlights:

  • NexGen knee implant linked to high failure rates was used in over 10,000 UK operations.
  • Concerns flagged as early as 2014; withdrawn from UK market in 2022.
  • Hundreds of patients required corrective surgery, with costs running into millions.
  • Manufacturer Zimmer Biomet says patient safety is its “top priority” but will not cover revision costs up front.

Implant used despite early warnings

A knee replacement implant used in thousands of NHS operations was known to have a concerning failure rate eight years before it was withdrawn, a BBC File on 4 Investigates report has found.

The NexGen implant, made by US manufacturer Zimmer Biomet, was fitted in more than 10,000 patients between 2012 and 2022. Concerns were first raised by the National Joint Registry (NJR) in 2014, though insufficient data at the time made it difficult to draw firm conclusions.

Keep ReadingShow less